by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
AusBioTALK NC R I S National Collaborative Research Infrastructure Strategy News from the NCRIS program Radpharm Scientific celebrates facility upgrade Canberra-based medical services provider Radpharm Scientific, a Division of Global Medical Solutions Australia Limited, recently celebrated the accomplishment of a major milestone in their business that is set to provide tangible benefits to Australian researchers seeking to progress their research to clinical trial. Representatives from the research community, industry, government and AusBiotech joined founder and CEO of Radpharm Scientific, Mr Ross Hanna, and his staff at the official opening ceremony held in April. The newly enhanced facility was declared open by AnnMarie Lansdowne, General Manager of the Research Infrastructure Branch of the Department of Innovation, Industry, Science and Research (DIISR). With support funding provided under the Commonwealth Government’s National Collaborative Research Infrastructure Strategy (NCRIS) Capability 5.5 Biotechnology Products, Radpharm has been able to upgrade its TGA-licensed aseptic ‘fill and finish’ facility and implement improvements in line with increasing regulatory requirements, as well as appoint additional staff. In return for this funding, Radpharm will provide eligible researchers requiring formulation, fill and finish of phase I/II clinical trial material at subsidised rates. This capability potentially provides great benefit to researchers seeking GMP manufacture of small batch sizes for the clinic. Historically it has been difficult for researchers to progress from drug discovery to GMP clinical manufacture within Australia. Anna Lavelle, CEO of AusBiotech, said: “Aside from the significant financial and regulatory challenges researchers have faced, the infrastructure and technical expertise required to help them along this path has been either non-existent or not readily accessible.” With support of NCRIS, Radpharm Scientific is now able to address a previously unmet need of Australian researchers seeking small batch sizes necessary for phase I/II clinical trials. www.radpharm.com.au AusBiotech is proud to be the managing agency for the Commonwealth Government’s NCRIS program for Capability 5.5 Biotechnology Products – Recombinant Proteins and Biofuels. AusBiotech is responsible for the allocation of $23 million of Commonwealth Funds for the development of facilities across Australia. When state government and host institution contributions are considered, the overall project value is $62 million. This project offers eligible researchers engaged in recombinant protein or biofuels research with access to quality facilities, advanced equipment and technical expertise at a subsidised rate. For more information on NCRIS Capability 5.5 Biotechnology Products and how to apply for access to NCRIS facilities, please contact: Ms Nicole Bleasdale, NCRIS Program Manager Tel: (03)9828 1416 Email: email@example.com www.ncrisproteins.org www.nrisbiofuels.org Manufacture of Recombinant Proteins and Biofuels Capability 5.5 Biotechnology Products